Fumic acid fonorase is a novel acid-suppressing drug—a potassium-competitive acid blocker (P-CAB). Fonorase reversibly inhibits the activity of H+, K+ -ATPase in a potassium-competitive manner; it remains in the gastric parietal cells for an extended period, thereby suppressing gastric acid secretion and effectively preventing damage to the upper gastrointestinal mucosa. Fumaric acid fonorase does not require acid activation; it achieves full efficacy rapidly from the first dose, with a strong, long-lasting and stable acid-suppressing effect. The acid-suppressing process is not affected by food intake, and it can be taken either before or after meals, thereby enhancing convenience of use.

Primary Indications

Reflux oesophagitis.

Used in combination with appropriate antibiotics to eradicate Helicobacter pylori.

The Main Contraindication To Medication

1. This product is contraindicated in patients who are allergic to any of its ingredients.

2. This product is contraindicated in patients currently being treated with azanavir or rilpivirine (see [Drug Interactions]).

3. For information on contraindications regarding the use of medications in combination with fonorase (clarithromycin, amoxicillin and potassium bismuth citrate), please refer to the ‘Contraindications’ section of their respective package leaflets.

Tablet